Antiviral Treatment Guidelines for Middle East Respiratory Syndrome

키워드

참고문헌 (48)

1. Zumla A, "Middle East respiratory syndrome", Lancet (2015)
2. "MERS Statistics"[URL]
3. "Middle East respiratory syndrome coronavirus (MERS-CoV)"[URL]
4. Stockman LJ, "SARS: systematic review of treatment effects", PLoS Med, 3, pp.e343~ (2006)
5. Omrani AS, "Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study", Lancet Infect Dis, 14, pp.1090~1095 (2014)
6. Shalhoub S, "IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study", J Antimicrob Chemother, 70, pp.2129~2132 (2015)
7. Arabi YM, "Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection", Ann Intern Med, 160, pp.389~397 (2014)
8. Assiri A, "Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study", Lancet Infect Dis, 13, pp.752~761 (2013)
9. Feikin DR, "Association of higher MERS-CoV virus load with severe disease and death, Saudi Arabia, 2014", Emerg Infect Dis (2015)
10. Saad M, "Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia", Int J Infect Dis, 29, pp.301~306 (2014)
11. Al-Abdallat MM, "Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description", Clin Infect Dis, 59, pp.1225~1233 (2014)
12. Al-Tawfiq JA, "Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study", Int J Infect Dis, 20, pp.42~46 (2014)
13. Momattin H, "Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy", Int J Infect Dis, 17, pp.e792~e798 (2013)
14. Peiris JS, "Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia:a prospective study", Lancet, 361, pp.1767~1772 (2003)
15. Falzarano D, "Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques", Nat Med, 19, pp.1313~1317 (2013)
16. Khalid M, "Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases", Antivir Ther, 20, pp.87~91 (2015)
17. Chan KS, "Treatment of severe acute respiratory syndrome with lopinavir", ritonavir: a multicentre retrospective matched cohort study, 2003, pp.9, 399~406
18. Chu CM, "Role of lopinavir", ritonavir in the treatment of SARS: initial virological and clinical findings, 2004, pp.59, 252~256
19. Chan JF, "Treatment with lopinavir", ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a non-human primate model of common marmoset, 2015, ~
20. Spanakis N, "Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen", Int J Antimicrob Agents, 44, pp.528~532 (2014)
21. Hart BJ, "Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays", J Gen Virol, 95, pp.571~577 (2014)
22. Vigant F, "Broad-spectrum antivirals against viral fusion", Nat Rev Microbiol, 13, pp.426~437 (2015)
23. Falzarano D, "Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin", Sci Rep, 3, pp.1686~ (2013)
24. Hirsch HH, "Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus", Clin Infect Dis, 56, pp.258~266 (2013)
25. de Wilde AH, "MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment", J Gen Virol, 94, pp.1749~1760 (2013)
26. Cheng VC, "Clinical management and infection control of SARS: lessons learned", Antiviral Res, 100, pp.407~419 (2013)
27. Payne DC, "Stillbirth during infection with Middle East respiratory syndrome coronavirus", J Infect Dis, 209, pp.1870~1872 (2014)
28. "Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected: Interim guidance"[URL]
29. "Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States"[URL]
30. Amato MP, "Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis", Neurology, 75, pp.1794~1802 (2010)
31. Sandberg-Wollheim M, "Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy", Mult Scler, 17, pp.423~430 (2011)
32. Knowles SR, "Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada", Clin Infect Dis, 37, pp.1139~1142 (2003)
33. Muller MP, "Adverse events associated with highdose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome", Pharmacotherapy, 27, pp.494~503 (2007)
34. Gara N, "What the infectious disease physician needs to know about pegylated interferon and ribavirin", Clin Infect Dis, 56, pp.1629~1636 (2013)
35. "Pegasys" (2002), Hoffman-La Roche Inc
37. Chan JF, "Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus", J Infect, 67, pp.606~616 (2013)
38. de Wilde AH, "Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture", Antimicrob Agents Chemother, 58, pp.4875~4884 (2014)
39. Chan JF, "Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease", Clin Microbiol Rev, 28, pp.465~522 (2015)
40. Stadler K, "Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level", Am J Respir Cell Mol Biol, 39, pp.142~149 (2008)
41. Raj VS, "Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus", J Virol, 88, pp.1834~1838 (2014)
42. Mair-Jenkins J, "The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis", J Infect Dis, 211, pp.80~90 (2015)
43. Cheng Y, "Use of convalescent plasma therapy in SARS patients in Hong Kong", Eur J Clin Microbiol Infect Dis, 24, pp.44~46 (2005)
44. Lee N, "Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients", J Clin Virol, 31, pp.304~309 (2004)
45. Wang H, "Fatal aspergillosis in a patient with SARS who was treated with corticosteroids", N Engl J Med, 349, pp.507~508 (2003)
46. Yam LY, "Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong", J Infect, 54, pp.28~39 (2007)
47. Levy MM, "Clinical issues and research in respiratory failure from severe acute respiratory syndrome", Am J Respir Crit Care Med, 171, pp.518~526 (2005)
48. So LK, "Development of a standard treatment protocol for severe acute respiratory syndrome", Lancet, 361, pp.1615~1617 (2003)

관련 논문AI추천